Insmed, Inc. (NASDAQ:INSM) Receives $205.41 Average Target Price from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twenty have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $205.4091.

Several research analysts have recently weighed in on INSM shares. Guggenheim cut their price objective on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. HC Wainwright decreased their price target on shares of Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. UBS Group upped their price objective on Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a report on Friday, October 31st. TD Cowen reduced their target price on Insmed from $269.00 to $241.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Finally, The Goldman Sachs Group increased their price target on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a report on Monday, December 15th.

Insider Buying and Selling at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $194.00, for a total value of $5,820,000.00. Following the completion of the transaction, the insider directly owned 36,461 shares in the company, valued at approximately $7,073,434. This represents a 45.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elizabeth M. Anderson sold 5,000 shares of Insmed stock in a transaction on Monday, November 24th. The stock was sold at an average price of $204.58, for a total transaction of $1,022,900.00. Following the sale, the director directly owned 58,729 shares in the company, valued at $12,014,778.82. This trade represents a 7.85% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 157,829 shares of company stock worth $30,266,463. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently bought and sold shares of INSM. Vanguard Group Inc. raised its position in shares of Insmed by 13.0% during the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after purchasing an additional 2,291,328 shares during the period. Norges Bank bought a new stake in Insmed in the second quarter valued at $194,728,000. Adage Capital Partners GP L.L.C. lifted its stake in Insmed by 109.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after buying an additional 1,799,382 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the period. Finally, Orbis Allan Gray Ltd acquired a new position in shares of Insmed during the second quarter valued at $153,389,000.

Insmed Price Performance

INSM stock opened at $176.34 on Tuesday. The stock has a market capitalization of $37.61 billion, a price-to-earnings ratio of -28.49 and a beta of 1.01. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. The stock’s fifty day simple moving average is $189.12 and its 200-day simple moving average is $147.91.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter last year, the company posted ($1.27) earnings per share. The business’s quarterly revenue was up 52.4% compared to the same quarter last year. Equities research analysts expect that Insmed will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.